New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2013
08:55 EDTBMRBioMed Realty Trust 15M share Spot Secondary priced at $21.40
The deal range was $20.95-21.60. Morgan Stanley, Raymond James, UBS, UBS, Wells Fargo and KeyBanc acted as joint book running managers for the offering.
News For BMR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2015
16:34 EDTBMROn The Fly: Top stock stories for Wednesday
Stocks began the day in quiet fashion and remained that way during the first hour of trading. Following the release of the weekly energy inventory report, the averages moved lower and looked to be possibly setting up for another selloff. Positive comments on China's economy by its President, who is visiting the U.S., brought out buyers, who pared the market's losses. The averages finished slightly in the red in a day marked by low volume as a number of market participants may have been absent in observance of the Jewish holiday of Yom Kippur. ECONOMIC EVENTS: In the U.S., Markit's flash manufacturing purchasing manager's index was flat at 53.0 in September, which was slightly better than the expectation for it to dip to 52.8. EIA inventory data showed a 1.93M barrel fall in crude oil inventories, versus expectations for a weekly drawdown of 1.25M barrels. In China, Markit's flash manufacturing PMI fell to 47.0 in September from 47.3 last month. In Europe, Markit's composite PMI for the eurozone came in at 53.9 in the first look for September, down from 54.3 in August and below expectations for a reading of 54.1. COMPANY NEWS: Shares of Volkswagen (VLKAY) trading in New York rebounded 6.5% to $27.10 following the resignation of Chief Executive Officer Martin Winterkorn, with the company's supervisory board subsequently praising the decision and saying it will consider his replacement at a meeting Friday. Prior to the CEO change news, the stock was downgraded at research firms JPMorgan, Deutsche Bank and Natixis to hold or equivalent ratings this morning. Accounting for today's advance, U.S.-listed shares of Volkwagen are still down nearly 29% since last Friday, when the EPA publicly accused the automaker of equipping certain diesel cars sold in the U.S. with software that circumvented emissions standards... Against the backdrop of China's President Xi Jinping visiting the U.S., Boeing (BA) announced deals to sell 300 planes to three Chinese companies and set up an aircraft factory in China. The deals are possibly worth tens of billions of dollars in total and represent the largest total order the planemaker has received from Chinese companies, according to Reuters. The Wall Street Journal reported, citing people familiar with the matter, that Cisco (CSCO) plans to announce a partnership with Chinese server maker Inspur Group during President Xi Jinping's visit. MAJOR MOVERS: Among the notable gainers was First Niagara (FNFG), which advanced $1.30, or 14.5%, to $10.26 following a Bloomberg report that the company is exploring a sale. DealReporter noted that potential suitors include Toronto-Dominion Bank (TD), Huntington Bancshares (HBAN) and New York Community Bancorp (NYCB). BioMed Realty (BMR) gained $2.36, or 12.3%, to $21.54 after Bloomberg reported that the company is in talks to sell itself and has attracted attention from firms including Blackstone (BX). Heron Therapeutics (HRTX) rose $7.25, or 21.6%, to $40.81 after announcing that its Phase 2 study of HTX-011 for post-operative pain met its primary endpoint. Shares of a competitor Pacira (PCRX) declined 7.65% after the news, with several analysts remarking that Heron's data compares favorably versus Pacira's Exparel drug. Summit Midstream Partners (SMLP) declined $3.90, or 18.2%, to $17.52 following a Bloomberg report that Energy Capital Partners is seeking to sell its stake in the company. Synchronoss (SNCR) fell 10.75% to $33.37 after research firm Baird said it has become "increasingly concerned" that Verizon (VZ) is "no longer fully committed" to the white-label cloud product it offers in conjunction with the cloud services provider. INDEXES: The Dow fell 50.58, or 0.31%, to 16,279.89, the Nasdaq lost 3.98, or 0.08%, to 4,752.74, and the S&P 500 declined 3.98, or 0.2%, to 1,938.76.
12:27 EDTBMROn The Fly: Top stock stories at midday
Subscribe for More Information
10:24 EDTBMRBioMed Realty surges after report of exploring sale
Shares of BioMed Realty Trust (BMR) are surging in morning trading following a Bloomberg report that said the company is in talks to sell itself. WHAT'S NEW: BioMed Realty Trust, a San Diego-based real estate investment trust with a market value of $3.9B, is exploring a sale, Bloomberg reported last night. According to sources, the company, which went public in 2004, has hired Morgan Stanley (MS) to explore a potential deal. WHAT'S NOTABLE: Bloomberg reported that BioMed Realty has attracted interest from firms including Blackstone Group (BX), explaining that buying REITs is a way for buyers like the private equity firm to put large amounts of cash to work. One source notes that talks remain ongoing and there is no guarantee a deal will be finalized. In July, Blackstone finalized an agreement to acquire shopping center REIT Excel Trust (EXL). ANALYST TAKE: Canaccord upgraded BioMed Realty to Buy from Hold following the Bloomberg report and raised its price target to $23 from $21. Analyst Paul Morgan said the M&A report highlights BioMed's "discounted" valuation to peers, reducing the emphasis on near-term earnings issues of asset sales and lease terminations. Morgan said the firm's preliminary $25 takeout valuation "could prove conservative" in case the M&A process is "competitive." Blackstone and other private equity players, Morgan said, have the "capacity" to look beyond short-term earnings challenges to extract value from REITs. PRICE ACTION: BioMed Realty Trust is up 11.7% to $21.42 in morning trading.
10:00 EDTBMROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Baidu (BIDU) upgraded to Buy from Underperform at CLSA... BioMed Realty (BMR) upgraded to Buy from Hold at Canaccord... Carnival (CCL) upgraded to Buy from Neutral at Nomura... (CTRP) upgraded to Buy from Outperform at CLSA... Daktronics (DAKT) upgraded to Buy from Hold at Needham... FMC Corporation (FMC) upgraded to Buy from Hold at Jefferies... Finish Line (FINL) upgraded to Outperform from Market Perform at FBR Capital... Intel (INTC) upgraded on potential PC, client business rebound at Bernstein... MTN Group (MTNOY) upgraded to Neutral from Sell at Goldman... Mitcham Industries (MIND) upgraded to Buy from Neutral at Sidoti... Parker Drilling (PKD) upgraded to Buy from Neutral at Sidoti... Raytheon (RTN) upgraded on international outlook at Bernstein... Regional Management (RM) upgraded to Buy from Hold at Jefferies... Vivendi (VIVHY) upgraded to Hold from Underperform at Jefferies... Wolverine World Wide (WWW) upgraded to Neutral from Sell at Citi.
09:09 EDTBMROn The Fly: Pre-market Movers
HIGHER: Heron Therapeutics (HRTX), up 20% after announcing results from its Phase 2 clinical study of its drug for the management of post-operative pain in patients undergoing bunionectomy... BioMed Realty Trust (BMR), up 10% after Bloomberg reported that the company is in talks to sell itself and has attracted interest from companies including Blackstone (BX) and Canaccord upgraded BioMed Realty to Buy... Citrix Systems (CTXS), up 2.5% after Reuters said the company is making a last-ditch attempt to sell itself as a whole company before beginning asset sales. LOWER: OncoGenex (OGXI), down 19% after the company reported that the addition of apatorsen to Abraxane and gemcitabine did not demonstrate a survival benefit compared to Abraxane and gemcitabine alone in a Phase 2 clinical study... Pacira Pharmaceuticals (PCRX), down 3.7% in the wake of Heron's new data, with several analysts stating that Heron's data compares favorably versus Pacira's Exparel drug.
08:56 EDTBMRBioMed Realty Trust volatility elevated into talks to sell itself report
Subscribe for More Information
06:23 EDTBMRBioMed Realty Trust in talks to sell itself, Bloomberg reports
Subscribe for More Information
06:15 EDTBMRBioMed Realty upgraded to Buy from Hold at Canaccord
Canaccord upgraded BioMed Realty to Buy following reports the company has engaged Morgan Stanley to advise in a potential takeout, with Blackstone Group being named as one of the interested suitors. The firm said the news highlights BioMed's discounted valuation and raised its price target to $23 from $21.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use